Adverse reactions occurring more often than in single cases are listed according to the following gradation: very often (> 10%); often (> 1%, <10%); infrequently (> 0.1%, <1%); rarely (> 0.01%, <0.1%); very rarely (<0.01%).
From the hematopoiesis: very often - leukopenia, myelosuppression, neutropenia, rarely - thrombocytopenia, anemia. The most significant decrease in the number of leukocytes is usually observed from 9 to 14 days (up to 25 days), platelets from 7 to 17 days of treatment. Very rarely - paitsitopeia, agranulocytosis.
From the immune system: very often immunosuppression with an increase in the incidence of infectious diseases, rarely generalized allergic reactions, anaphylactic shock, the frequency of unknown development of secondary infections, sepsis.
Endocrine disorders: frequency is unknown increase in total thyroxine (T4) and triiodothyronine (T3) and blood plasma without increasing the content of free T4 and thyroid-stimulating hormone (TSH) and without clinical signs of hyperthyroidism.
From the side of nutrition and metabolism: infrequently hyperuricemia.
From the digestive system: very often - anorexia, decreased appetite, inflammation and / or ulceration of the mucous membranes of the gastrointestinal tract (including stomatitis, glossitis, pharyngitis, esophagitis, mucositis, proctitis), often - diarrhea, nausea, vomiting, infrequently - dehydration, bleeding gastrointestinal tract, damage to liver cells, impaired liver function, very rarely cholecystitis, liver necrosis, incl. with a fatal outcome, the frequency is unknown - heartburn, taste change.
From the cardiovascular system: very often - ischemic changes pas ECG, dilated cardiomyopathy, often - pain in the heart, rarely - arrhythmias, ischemia, decreased blood pressure, rarely myocardial infarction, heart failure, myocarditis, cardiomyopathy, cardiogenic shock, the peripheral cerebral circulation, Raynaud's syndrome, thrombophlebitis, thromboembolism, very rarely angina, cardiac arrest, sudden death.
From the nervous system: often - cerebellar ataxia, impaired sensitivity, snotty, euphoria, nystagmus, retrobulbar neuritis, headache, infrequently,transient cerebral syndrome (ataxia, confusion, extrapyramidal movement disorders and cortical disorders), very rarely - leukoencephalopathy with symptoms such as ataxia, speech impairment, disorientation, myasthenia gravis, aphasia, seizures, coma (after application in high doses or in patients with insufficiency of dihydropyrimidine dehydrogenase), cerebral infarction (with combined therapy with cisplatin and mitomy).
From the respiratory system, chest and mediastinum: very often - nosebleeds, bronchospasm, cough, shortness of breath.
From the sense organs: rarely - conjunctivitis, irritation of the eye mucosa, excessive lacrimation due to duct stenosis, photophobia, optic neuritis, cataract, cortical blindness (at high doses), diplopia, visual impairment, blepharitis, eyelid reversal, limitation of eye mobility.
On the part of the reproductive system: infrequently - reversible oppression of the sexual glands, leading to amenorrhea or azoospermia.
From the skin, subcutaneous tissues and skin appendages: very often - alopecia (reversible), syndrome of palmar-plantar erythrodysesthesia (sensation of tingling in the hands and feet, followed by the appearance of pain, hyperemia and swelling), infrequently - hyperpigmentation of the skin, depigmentation of the skin in the form of bands near the veins, itching of the skin, rash, change (onycholysis, pain and thickening of the nail bed, paronychia) and convergence of the nail plate, dry and cracked skin, erythema, telangiectasia, rarely - photosensitivity.
Allergic reactions: rarely - skin rash, dermatitis, urticaria, hyperemia of the skin of the palms and soles.
Other: infrequently - fever, weakness, thrombophlebitis at the injection site.